Compare COOK & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | BMEA |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.6M | 140.3M |
| IPO Year | 2021 | 2021 |
| Metric | COOK | BMEA |
|---|---|---|
| Price | $49.53 | $1.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $53.00 | $9.83 |
| AVG Volume (30 Days) | 13.8K | ★ 2.3M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.87 |
| 52 Week High | $86.59 | $2.99 |
| Indicator | COOK | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 35.10 | 61.74 |
| Support Level | $47.15 | $1.17 |
| Resistance Level | $77.25 | $2.03 |
| Average True Range (ATR) | 2.41 | 0.15 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 14.19 | 52.44 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.